100 -5 (67) 2024 - Usmanov I., Abdullayeva F.O. - GOING BACK TO THE OLD ONE. TUBERCULOSIS IS A GLOBAL THREAT TO HUMANITY

GOING BACK TO THE OLD ONE. TUBERCULOSIS IS A GLOBAL THREAT TO HUMANITY

Usmanov I. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Abdullayeva F.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Atayeva A.O. - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

Tuberculosis is one of the 10 leading causes of death worldwide and the leading cause of death from infections. Tuberculosis is a chronic infectious bacterial disease caused by the pathogen Mycobacterium tuberculosis complex (popularly known as Koch's wand). In the Republican specialized scientific and practical Medical Center of phthisiology and Pulmonology "Gazeta.uz" reported that in Uzbekistan, the incidence rate last year was 32.1 per 100 thousand population. At the same time, the mortality rate from the disease is about 1.2 out of 100,000 people per year (2022). With the advent of antibiotics, a person managed to take control of such a common and dangerous infectious disease as tuberculosis (the old name is consumption). The successful fight against tuberculosis is influenced by the development and implementation of new methods of prevention, diagnosis and treatment of tuberculosis diseases that meet modern requirements. The work is carried out jointly with WHO and other international organizations.

Key words: Tuberculosis is a global threat to humanity, death from infections, treatment of tuberculosis diseases.

First page

576

Last page

582

For citation:Usmanov I., Abdullayeva F.O., Atayeva A.O. - GOING BACK TO THE OLD ONE. TUBERCULOSIS IS A GLOBAL THREAT TO HUMANITY//New Day in Medicine 5(67)2024 576-582 https://newdayworldmedicine.com/en/article/3758

List of References

  1. Николенко Н.Ю., Кудлай Д.А., Борисов С.Е., Санникова Т.Е., Докторова Н.П. Оценка клинико-экономической эффективности различных режимов этиотропной химиотерапии у больных туберкулезом органов дыхания с множественной и широкой лекарственной устойчивостью. //Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2023; 16(2):162–175. https://doi. org/10.17749/2070-4909/farmakoekonomika. 2023.179
  2. Гайда А.И., Абрамченко А.В., Романова М.И., Можокина Г.Н., Самойлова А.Г., Васильева И.А. Клиническая эффективность и безопасность клофазимина в схемах лечения туберкулеза с лекарственной устойчивостью (метаанализ) //Туберкулёз и болезни лёгких. – 2024;102(2):20–29. http://doi.org/10.58838/2075-1230-2024- 102-2-20-29
  3. Ahmad N., Ahuja S.D., Akkerman O.W., Alffenaar J.C., Anderson L.F., Baghaei P., Bang D., Barry P.M. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. //Lancet, 2018;392(10150):821-834.
  4. Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: Should different standards be applied? //International Journal Tuberculosis and Lung Diseases, International Union against Tubercul. and Lung Dis., 2017;21(12):1211-1213.
  5. Du Y., Qiu C., Chen X., Wang J., Jing W., Pan H., Chen W., Liu Y., Li C., Xi X., Yin H., Zeng J., Zhang X., Xu T., Wang Q., Guo R., Wang J., Pang Y., Chu N. Treatment outcome of a shorter regimen containing clofazimine for multidrug-resistant tuberculosis: a randomized a randomized control trial in China. //Clin. Infect. Dis., 2020;71(4):1047-1054.
  6. Duan H., Chen X., Li Z., Pang Y., Jing W., Liu P., Wu T., Cai C., Shi J., Qin Z., Yin H., Qiu C., Li C., Xia Y., Chen W., Ye Z., Li Z., Chen G., Wang S., Liu Y., Chu L., Zhu M., Xu T., Wang Q., Wang J., Du Y., Wang J., Chu N., Xu S. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin. Microbiol. Infect., 2019;25(2):190-195.
  7. Fu L., Weng T., Sun F., Zhang P., Li H., Li Y., Yang Q., Cai Y., Zhang X., Liang H., Chen X., Wang Z., Liu L., Zhang W., Deng G. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int. J. Infect. Dis., 2021, no. 111, pp. 138-147. 15. Global tuberculosis report 2022. Geneva, World Health Organization, 2022. Licence: CC BY-NC-SA 3.0 IGO
  8. Li G., Xu Z., Jiang Y., Liu H., Zhao Li-Li, Li M. et al. Synergistic activities of clofazimine with moxifloxacin or capreomycin against Mycobacterium tuberculosis in China. //Int. J. Antimicrob. Agents, 2019;54(5):642-646.
  9. Nyang'wa B-T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Solodovnikova V., Liverko I., Moodliar R., Dodd M., Ngubane N., Rassool M., McHugh T.D., Spigelman M., Moore D.AJ., Ritmeijer K., du Cros P., Fielding K.; TB-PRACTECAL Study Collaborators. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis //N Engl J Med. 2022;387(25):2331-2343.
  10. Riccardi N., Alagna R., Saderi L., Ferrarese M., Castellotti P., Mazzola E., De Lorenzo S., Viggiani P., Udwadia Z., Besozzi G., Cirillo D., Sotgiu G., Codecasa L.; for StopTB Italia Onlus Group. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres //BMC Infect Dis. 2019;19(1):564.
  11. Stadler J.AM., Maartens G., Meintjes G., Wasserman SЮ Clofazimine for the treatment of tuberculosis // Front. Pharmacol. – 2023. – № 14. – Р.1100488. 20. Swanson R.V., Ammerman N.C., Ngcobo B., Adamson J., Moodley C., Dorasamy A., et al. Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy // Antimicrob. Agents Chemother. ‒ 2016. ‒ Vol. 60, № 5. ‒ Р. 2864-2869.
  12. World Health Organization et al. WHO consolidated guidelines on drug-resistant tuberculosis treatment. – World Health Organization, 2019. 22. World Health Organization et al. WHO treatment guidelines for drug-resistant tuberculosis. – World Health Organization, 2016.
  13. Nyang'wa B-T., Berry C., Kazounis E., Motta I., Parpieva N., Tigay Z., Solodovnikova V., Liverko I., Moodliar R., Dodd M., Ngubane N., Rassool M., McHugh T.D., Spigelman M., Moore D.AJ., Ritmeijer K., du Cros P., Fielding K.; TB-PRACTECAL Study Collaborators. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N. Engl. J. Med., 2022, vol. 387, no. 25, pp. 2331-2343.
  14. Riccardi N., Alagna R., Saderi L., Ferrarese M., Castellotti P., Mazzola E., De Lorenzo S., Viggiani P., Udwadia Z., Besozzi G., Cirillo D., Sotgiu G., Codecasa L.; for StopTB Italia Onlus Group. Towards tailored regimens in the treatment of drug-resistant tuberculosis: a retrospective study in two Italian reference Centres. BMC Infect Dis., 2019, vol. 19, no. 1, pp. 564.
  15. Stadler J.AM., Maartens G., Meintjes G., Wasserman S. Clofazimine for the treatment of tuberculosis. Front. Pharmacol., 2023, no. 14, pp. 1100488. 20. Swanson R.V., Ammerman N.C., Ngcobo B., Adamson J., Moodley C., Dorasamy A. et al. Clofazimine contributes sustained antimicrobial activity after treatment cessation in a mouse model of tuberculosis chemotherapy. Antimicrob. Agents Chemother., 2016, vol. 60, no. 5, pp. 2864-2869.
  16. World Health Organization et al. WHO consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, 2019. 22. World Health Organization et al. WHO treatment guidelines for drug-resistant tuberculosis. World Health Organization, 2016.

    file

    download